Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker LSTA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Adva… NCT05712356 · Cholangiocarcinoma, Gallbladder Cancer certepetide, Durvalumab | LSTA Lisata Therapeutics, Inc. | Phase 2 | Completed | 66 | Apr 5, 2026 | Registry ↗ |
| May 4, 2026 | A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction NCT04614467 · Coronary Microvascular Dysfunction, Coronary Microvascular… CLBS16, Placebo | LSTA Lisata Therapeutics, Inc. | Phase 2 | Terminated | 34 | Sep 28, 2022 | Registry ↗ |
| Jun 6, 2025 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC NCT06592664 · Pancreas Cancer, Pancreatic Carcinoma certepetide, nab-paclitaxel | LSTA Lisata Therapeutics, Inc. | Phase 1/2 | Withdrawn | 0 | Jan 2035 | Registry ↗ |
| Oct 9, 2024 | CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM) NCT04990427 · Chronic Kidney Diseases CLBS201 | LSTA Lisata Therapeutics, Inc. | Phase 1 | Completed | 6 | Jan 26, 2023 | Registry ↗ |
| Oct 9, 2024 | CLBS119 for Repair of COVID-19 Induced Pulmonary Damage NCT04522817 · Covid-19 CLBS119 | LSTA Lisata Therapeutics, Inc. | Phase 1 | Withdrawn | 0 | May 2021 | Registry ↗ |
| Oct 9, 2024 | Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) NCT02501018 · Critical Limb Ischemia, Buerger Disease CLBS12, SOC | LSTA Lisata Therapeutics, Inc. | Phase 2 | Completed | 33 | May 19, 2022 | Registry ↗ |
| Aug 28, 2024 | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer NCT03517176 · Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma CEND-1, Nab-paclitaxel | LSTA Lisata Therapeutics, Inc. | Phase 1 | Completed | 30 | Jun 19, 2020 | Registry ↗ |
| Oct 4, 2023 | Vaccine Therapy in Treating Patients With Kidney Cancer NCT00014131 · Kidney Cancer Biological/Vaccine: therapeutic autologous dendritic cells. | LSTA Lisata Therapeutics, Inc. | Phase 1 | Terminated | 9 | Dec 2009 | Registry ↗ |
| Jan 26, 2021 | ACT34-CMI -- Adult Autologous CD34+ Cells NCT00300053 · Myocardial Ischemia CLBS14 (low-dose), CLBS14 (high-dose) | LSTA Lisata Therapeutics, Inc. | Phase 2 | Completed | 321 | Mar 2008 | Registry ↗ |
| Jan 8, 2021 | Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and… NCT03508609 · Coronary Microvascular Dysfunction CLBS16 | LSTA Lisata Therapeutics, Inc. | Phase 2 | Completed | 20 | Dec 10, 2019 | Registry ↗ |
| Jan 8, 2021 | Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project… NCT02691247 · Diabetes Mellitus CLBS03 Low Dose, CLBS03 High Dose | LSTA Lisata Therapeutics, Inc. | Phase 2 | Completed | 113 | Mar 2019 | Registry ↗ |
| May 10, 2019 | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma NCT01875653 · Stage IV Melanoma, Stage III Melanoma Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC),… | LSTA Lisata Therapeutics, Inc. | Phase 3 | Terminated | 4 | Jan 2016 | Registry ↗ |
| May 10, 2019 | Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Gliobl… NCT00814593 · Brain and Central Nervous System Tumors lymphokine-activated killer cells, polifeprosan 20 with car… | LSTA Lisata Therapeutics, Inc. | Phase 2 | Withdrawn | 0 | Apr 2011 | Registry ↗ |
| Dec 19, 2018 | Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exe… NCT01508910 · Chronic Myocardial Ischemia, Refractory Angina Pectoris Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD3… | LSTA Lisata Therapeutics, Inc. | Phase 3 | Completed | 291 | Nov 2015 | Registry ↗ |
| Nov 28, 2018 | ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study) NCT00545610 · Myocardial Ischemia | LSTA Lisata Therapeutics, Inc. | — | Completed | 150 | Apr 2010 | Registry ↗ |
| Apr 28, 2016 | NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction NCT01495364 · ST Segment Elevation Myocardial Infarction NBS10, placebo | LSTA Lisata Therapeutics, Inc. | Phase 2 | Completed | 195 | Jun 2014 | Registry ↗ |
16 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances